SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-042770
Filing Date
2022-11-22
Accepted
2022-11-22 16:06:02
Documents
13
Period of Report
2022-11-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10044587_8k.htm   iXBRL 8-K 40146
2 EXHIBIT 10.1 brhc10044587_ex10-1.htm EX-10.1 64055
  Complete submission text file 0001140361-22-042770.txt   257578

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20221122.xsd EX-101.SCH 3866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221122_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221122_pre.xml EX-101.PRE 16045
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10044587_8k_htm.xml XML 4238
Mailing Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121
Business Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221410335
SIC: 2834 Pharmaceutical Preparations